NAC-GED 5% gel promising treatment option for moderate to severe acne
A promising treatment option is NAC-GED 5% gel for moderate to severe acne, according to a recent study published in the British Journal of Dermatology.
Preliminary in vitro and in vivo studies have shown that the peroxisome proliferator-activated receptor-γ modulator N-acetyl-GED-0507-34-LEVO (NAC-GED) for the treatment of acne-stimulating sebaceous cell differentiation. Effectiveness of. It improves sebum composition and controls the inflammatory process.
A group of researchers conducted a study to evaluate the efficacy and safety of NAC-GED (5% and 2%) in patients with moderate to severe facial crusts Vulgaris.
This double-blind phase II randomized controlled trial was conducted at 36 sites in Germany, Italy, and Poland. Patients aged 12-30 years with facial acne, Investigator Global Assessment (IGA) score 3-4, inflammatory and non-inflammatory lesions 20-100 years (2% or 5%) were randomly assigned to topical application of study drug or placebo. . vehicle), once a day for 12 weeks. Primary efficacy endpoints were rate of change in total disease count (TLC) from baseline and the 12-week IGA success rate. Safety endpoints were adverse events (AEs) and serious AEs.
The results of the survey are as follows.
• Between Q1 2019 and Q1 2020, 450 patients had NAC-GED 5% (n = 150), NAC-GED 2% (n = 150), or vehicle (n =). Randomly assigned. up to 150).
• The rate of change in TLC reduction was statistically significantly higher in both the NAC-GED 5% and NAC-GED 2% groups compared to vehicles.
• A greater percentage of patients treated with NAC-GED 5% experienced IGA success compared to the vehicle group.
• The success rate of IGA in the 2% NAC-GED group was 33%.
• The proportion of patients with one or more AEs in the NAC-GED group was 5%, NAC-GED 2% and vehicles were 19%, 16% and 19%, respectively.
Therefore, topical application of NAC-GED 5% reduced TLC, increased the success rate of IGA, and could be safely used in patients with scaly plaques. Therefore, the new PPARγ modulator, NAC-GED, showed an effective clinical response.
Reference:
Picardo, M., Cardinali, C., La Placa, M., Lewartowska-Białek, A., Lora, V., Micali, G., Montisci, R., Morbelli, L., Nova, A., Parodi, A., Reich, A., Sebastian, M., Turek-Urasińska, K., Weirich, O., Zdybski, J., Zouboulis, C.C. and (2022), Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to-severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial. Br J Dermatol. https://doi.org/10.1111/bjd.21663
Keywords:
Mauro Picardo, Carla Cardinali, Michelangelo La Placa, Anita Lewartowska-Białek, Viviana Lora, Giuseppe Micali, Roberta Montisci, Luca Morbelli, Andrea Nova, Aurora Parodi, Adam Reich, Michael Sebastian, Katarzyna Turek-Urasińska, Oliver Weirich, Jacek Zdybski, Christos C. Zouboulis, the GEDACNE Study Group, Efficacy, safety, N-acetyl-GED-0507-34, LEVO, gel, patients, moderate-to severe, facial, acne, vulgaris, phase IIb, randomized, double-blind, vehicle-controlled trial, British Journal of Dermatology
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.